190 related articles for article (PubMed ID: 21150715)
1. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
2. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
3. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
[TBL] [Abstract][Full Text] [Related]
7. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Van De Voort TJ; Felder MA; Yang RK; Sondel PM; Rakhmilevich AL
J Immunother; 2013 Jan; 36(1):29-40. PubMed ID: 23211623
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL
Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467
[TBL] [Abstract][Full Text] [Related]
10. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
11. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
[TBL] [Abstract][Full Text] [Related]
12. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
Buhtoiarov IN; Lum HD; Berke G; Sondel PM; Rakhmilevich AL
J Immunol; 2006 Jan; 176(1):309-18. PubMed ID: 16365423
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
15. Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.
Shi Y; Felder MA; Sondel PM; Rakhmilevich AL
Mol Immunol; 2015 Aug; 66(2):208-15. PubMed ID: 25829245
[TBL] [Abstract][Full Text] [Related]
16. T-cell-independent antitumor effects of CD40 ligation.
Rakhmilevich AL; Alderson KL; Sondel PM
Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
20. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
